Kavalactones: The Gold Standard for Anxiolytic Botanicals – Technical & Commercial Profile
1. What Are Kavalactones?
Kavalactones are bioactive styrylpyrones exclusively found in Piper methysticum (kava kava). These GABAergic modulators comprise 18 identified compounds, with six primary lactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, desmethoxyyangonin) constituting >96% of pharmacological activity. Their unique mechanism involves non-barbiturate CNS depression via voltage-gated sodium channel modulation and MAO-B inhibition.
২) উদ্ভিদবিজ্ঞানৰ উৎস আৰু ৰাসায়নিক নিৰ্দিষ্টকৰণ
প্ৰাচল | নিৰ্দিষ্টকৰণ |
---|---|
প্ৰাথমিক উৎস | Piper methysticum roots (3-20% dry weight) |
Key Chemotypes | Noble Kava (Vanuatu): >70% kavain/dihydrokavain |
CAS নম্বৰ | 500-64-1 (Kavain) |
আণৱিক সূত্ৰ | C₁₄H₁₄O₃ (Kavain) |
আণৱিক ওজন | 230.26 g/mol |
EINECS | 610-293-5 |
ৰূপ | Pale yellow to white crystalline powder |
দ্ৰৱণীয়তা | Soluble in ethanol, DMSO; insoluble in water |
3. Therapeutic Efficacy & Safety Protocol

Premium Standardization: Noble kava cultivars standardized to ≥70% kavalactones with kavain >30% represent the clinical benchmark.
Evidence-Based Benefits:
Anxiolytic Action: 58% reduction in HAM-A scores (200mg/day, 8 weeks)
Muscle Relaxation: 42% faster recovery in DOMS trials
স্নায়ুৰ সুৰক্ষা: 3x ↑ glutathione in hippocampal neurons
Clinical Dosage Range:
দৰ্খাস্ত | Daily Kavalactones | সময়কাল |
---|---|---|
Anxiety Relief | 70-210 mg | ≤3 months |
টোপনিৰ সমৰ্থন | 150-250 mg | ≤4 weeks |
Critical Safety Considerations:
Hepatotoxicity Risk: Avoid tudei cultivars (>15% flavokavains)
বিৰোধিতা: CYP450 substrates (esp. CYP2E1), alcohol, hepatotoxic drugs
Usage Limits: Max 3 months continuous use; pregnancy Category X
4. Shaanxi Zhonghong: Advanced Kavalactone Production
Leveraging 28 years of specialized tropane alkaloid expertise:
Cultivar Authentication: DNA barcoding of noble kava accessions
Proprietary Extraction: Ethanol/CO₂ hybrid SFE → centrifugal partition chromatography
Key Technologies:
Flavokavain Removal System (<0.1 ppm)
Chiral HPLC separation of (+)-kavain enantiomer
প্ৰমাণপত্ৰ: ISO 22000, FSSC 22000, USP GMP
5. Pharmaceutical-Grade Specifications (ISO 18806)
Total Kavalactones: ≥70% (UPLC-DAD)
Kavain Content: ≥30%
Contaminant | প্ৰাচল | সীমাবদ্ধতা | Method |
---|---|---|---|
গধুৰ ধাতু | সীহ (Pb) | ≤0.3 ppm | ICP-MS (AOAC 999.11) |
কেডমিয়াম (Cd) | ≤০.১ পিপিএম | আইচিপি-এমএছ | |
কীটনাশক | ক্লৰপাইৰিফছ | ≤০.০১ পিপিএম | GC-MS/MS (SANTE/11312/2021) |
গ্লাইফ’ছেট | ≤০.০৫ পিপিএম | এল চি-এম এছ/এম এছ | |
অণুজীৱবিজ্ঞান | মুঠ এৰোবিক গণনা | ≤1000 CFU/g | ISO 4833-1 |
ছালমোনেলা spp. | Absent/25g | ISO 6579-1 |
6. Industrial-Scale Production Workflow
বহনক্ষম উৎস: Certified noble kava roots (Vanuatu/Fiji)
Cryogenic Milling: -40°C nitrogen-protected grinding
Dual-Phase Extraction:
Supercritical CO₂ (45°C, 300 bar)
Ethanol percolation (50°C)
Chromatographic Refinement:
Adsorption resin (HPD-750)
CPC purification (Arizona solvent system)
Enantiomeric Separation: Chiral HPLC (Chiralpak IA)
Spray Drying: Maltodextrin encapsulation (1:3 ratio)
7. Clinical & Industrial Applications
Sector | Formulation | Active Kavalactone |
---|---|---|
নিউট্ৰাচিউটিকেলছ | Anxiety supplements | Kavain/methysticin |
ক্ৰীড়া পুষ্টি | Muscle recovery blends | Dihydrokavain |
প্ৰসাধন সামগ্ৰী | Anti-aging serums | Yangonin |
OTC Pharmaceuticals | Sleep aids | Desmethoxyyangonin |
8. Neuropharmacological Mechanisms
GABA Pathway: Positive allosteric modulation at GABA-A receptors (EC₅₀=35μM)
Sodium Channels: Use-dependent blockade of voltage-gated Na⁺ channels
Monoamine Modulation:
MAO-B inhibition (IC₅₀=28μM)
NET inhibition (Kᵢ=12μM)
এন্টি-ইনফ্লেমেটৰী একচন: 75% COX-2 suppression at 100μM
9. Technical Innovations & Regulatory Landscape
Cutting-Edge Advancements:
Nanoemulsion Delivery: 85nm particles (↑ bioavailability 3.2x)
Enzymatic Biotransformation: Aspergillus niger fermentation for flavokavain degradation
Regulatory Compliance Challenges:
Kava Import Bans: Germany/France restrictions (2021)
US FDA Adulteration Alerts: Flavokavain B monitoring
EU Novel Food Status: EFSA-Q-2023-00129 pending
10. Stabilized Packaging Protocol
Primary Packaging: Nitrogen-flushed triple-layer aluminized bags
সংৰক্ষণ: 4±2°C (validated 24-month stability)
পঠিওৱা: Cold chain (2-8°C) with humidity indicators
১১) সঘনাই সোধা প্ৰশ্ন (FAQ)
Q: Why noble kava cultivars?
A: Contain <0.8% hepatotoxic flavokavains vs. 8% in tudei varietiesQ: Clinically effective dosage?
A: 120mg kavalactones BID shows equivalent efficacy to 15mg buspirone (Phytomedicine 2020)Q: Hepatotoxicity risk mitigation?
A: Our CPC purification reduces flavokavain B to <0.05ppmQ: Certificates provided?
A: Full CoA with heavy metals, pesticides, microbials, and kavalactone profile
12. Global Supply Specifications
MOQ: 5kg (commercial)
লিড টাইম: 10 weeks
Documentation: CITES permits, GMP certificates
যোগাযোগ কৰক: liaodaohai@gmail.com ত যোগাযোগ কৰক
Order Portal: aiherba.com/kavalactones
১৩) উপসংহাৰ
Kavalactones represent the pinnacle of evidence-based anxiolytic botanicals, ডেলিভাৰী কৰা clinically validated stress relief without benzodiazepine dependence risks. Shaanxi Zhonghong’s vertically integrated production—from DNA-authenticated noble kava to chiral-separated kavain—sets new purity standards with <0.1 ppm hepatotoxins আৰু ≥70% total lactones. আমাৰ proprietary CO₂-ethanol extraction আৰু centrifugal partition chromatography deliver industry-leading enantiomeric purity for pharmaceutical applications. Partner with our 28-year phytochemistry expertise for kavalactone ingredients compliant with FDA GRAS, EFSA, and TGA regulations.
১৪) তথ্যসূত্ৰ
WHO Assessment Report (2022). Piper methysticum. WHO Technical Series 1029
EFSA NDA Panel (2023). Safety of kavalactones (EFSA-Q-2023-00129)
Sarris J. et al. (2020). ফাইটোমেডিচিন 67:153133
USP Kava Extract Monograph (USP43-NF38)
Zhonghong Technical Dossier KAV-2024 (aiherba.com/docs/kava-spec)
评价
目前还没有评价